Viridian Therapeutics saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 70 to 78.
IBD's proprietary RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History shows that the market's biggest winners often have an RS Rating of above 80 in the early stages of their moves. See if Viridian Therapeutics can continue to show renewed price strength and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Viridian Therapeutics is now considered extended and out of buy range after clearing an 18.27 buy point in a first-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Viridian Therapeutics showed 0% earnings growth in its most recent report. Revenue rose 29%.
Viridian Therapeutics earns the No. 178 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
